Literature DB >> 19232508

Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.

Børre Fevang1, Jesper Eugen-Olsen, Arne Yndestad, Frank Brosstad, Klaus Beiske, Pål Aukrust, Stig S Frøland.   

Abstract

Common variable immunodeficiency (CVID) is a heterogeneous syndrome characterized by defective immunoglobulin production and high frequency of bacterial infections, autoimmunity and manifestations of chronic inflammation. The urokinase plasminogen activator (uPA), its cell bound and soluble receptor (uPAR, suPAR) have complex biological functions involving innate immune defense mechanisms and regulation of inflammation. Based on this dual role, we hypothesized that the uPA system could be affected in CVID, and examined expression of components of the uPA system in subgroups of CVID. All CVID-patients had increased plasma levels of suPAR with particularly high levels in those with splenomegaly and thrombocytopenia. Plasma uPA levels were also raised in these patients, and both suPAR and uPA levels correlated with the monocyte activation marker neopterin. Monocytes from CVID patients had increased expression of uPAR. We show an increased activation of the uPA system possibly contributing to the inflammatory phenotype seen in subgroups of CVID patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232508     DOI: 10.1016/j.clim.2009.01.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study.

Authors:  Paulo Rabna; Andreas Andersen; Christian Wejse; Ines Oliveira; Victor Francisco Gomes; Maya Bonde Haaland; Peter Aaby; Jesper Eugen-Olsen
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

2.  Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia.

Authors:  T Mölkänen; E Ruotsalainen; C W Thorball; A Järvinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

3.  Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.

Authors:  Hale Çitlenbik; Emel Ulusoy; Anıl Er; Aykut Çağlar; Fatma Akgül; Tuncay Küme; Durgül Yılmaz; Murat Duman
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-09-17       Impact factor: 1.349

4.  Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.

Authors:  B Suberviola; A Castellanos-Ortega; A Ruiz Ruiz; M Lopez-Hoyos; M Santibañez
Journal:  Intensive Care Med       Date:  2013-08-16       Impact factor: 17.440

5.  Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children.

Authors:  Rachida Tahar; Catarina Albergaria; Neil Zeghidour; Vincent Foumane Ngane; Leonardo K Basco; Christian Roussilhon
Journal:  Malar J       Date:  2016-06-29       Impact factor: 2.979

6.  Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.

Authors:  Tomasz W Kamiński; Krystyna Pawlak; Małgorzata Karbowska; Michał Myśliwiec; Dariusz Pawlak
Journal:  BMC Nephrol       Date:  2017-01-25       Impact factor: 2.388

7.  Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome.

Authors:  Xiao-Ling Wu; Ding Long; Li Yu; Jun-Hui Yang; Yuan-Chao Zhang; Feng Geng
Journal:  World J Emerg Med       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.